Critical Therapeutics to Present at the Cowen and Company 27th Annual Health Care Conference.

LEXINGTON, Mass. -- Critical Therapeutics, Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the development and commercialization of products for respiratory, inflammatory and critical care diseases, will present at the Cowen and Company 27th Annual Health Care Conference on March 13, 2007 at 4:00 PM ET from The Boston Marriott Copley Place Hotel.

Frank Thomas, President and Chief Executive Officer, will provide an update on the Company's strategy, operations and pipeline programs. A live and archived webcast of this presentation will be available by logging on to the "Investors" section of the Company's website, www.crtx.com, and clicking the link labeled "Webcasts & Presentations."

About Critical Therapeutics

Critical Therapeutics, Inc. is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to ZYFLO[R] (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma in patients 12 years of age and older. Critical Therapeutics is working to expand its zileuton franchise by developing a twice daily, controlled-release formulation for the prevention and chronic treatment of asthma and an injectable formulation for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is collaborating with MedImmune, Inc. to design antibody therapies that treat acute and chronic diseases triggered by the inflammatory cytokine HMGB1. Research pipeline programs include lifecycle management to extend the zileuton franchise and an alpha-7 project for the treatment of inflammation. Critical Therapeutics is located in Lexington, Mass. For more information, please visit www.crtx.com.